The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| LGND | +74.05% | +129.27% | +18.03% | +596% |
| S&P | +17.45% | +75.43% | +11.88% | +1,390% |
Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.
A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $59.67M | 39.4% |
| Gross Profit | $48.58M | 53.2% |
| Gross Margin | 81.42% | 7.3% |
| Market Cap | $3.72B | 83.8% |
| Market Cap / Employee | $79.17M | 0.0% |
| Employees | 47 | -30.9% |
| Net Income | $44.78M | 244.1% |
| EBITDA | $28.18M | 158.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $174.93M | 141.9% |
| Accounts Receivable | $59.60M | 55.3% |
| Inventory | 9.1 | -35.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $450.40M | 7645.4% |
| Short Term Debt | $1.10M | -15.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 9.95% | 10.4% |
| Return On Invested Capital | 2.54% | -9.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $45.91M | 66.1% |
| Operating Free Cash Flow | $45.92M | 61.9% |
| Metric | Q2 2024 | Q3 2024 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 36.45 | 39.82 | 85.26 | 32.40 | 135.84% |
| Price to Book | 2.42 | 2.75 | 4.15 | 3.91 | 63.67% |
| Price to Sales | 11.12 | 12.08 | 14.55 | 14.91 | 22.55% |
| Price to Tangible Book Value | 7.34 | 8.86 | 12.14 | 9.09 | 18.40% |
| Price to Free Cash Flow TTM | 39.97 | 42.56 | 119.26 | 81.72 | 281.04% |
| Enterprise Value to EBITDA | -66.38 | 108.60 | 54.75 | 131.82 | -19.42% |
| Free Cash Flow Yield | 2.5% | 2.3% | 0.8% | 1.2% | -73.76% |
| Return on Equity | -16.6% | -9.5% | 5.4% | 13.5% | -2658.23% |
| Total Debt | $4.45M | $5.74M | $451.00M | $451.49M | 6254.55% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
